Molecular Heterogeneity Has a Major Impact on the Measurement of Circulating N-Terminal Fragments of A- and B-Type Natriuretic Peptides
- 1 September 2004
- journal article
- Published by Oxford University Press (OUP) in Clinical Chemistry
- Vol. 50 (9) , 1576-1588
- https://doi.org/10.1373/clinchem.2004.032490
Abstract
The N-terminal fragments of A- and B-type natriuretic peptides (NT-proANP and NT-proBNP) are powerful markers of cardiac function. The current assays require refinement with regard to standardization with native calibrators and the ability to detect the actual circulating forms. The following peptides were prepared with recombinant methods: NT-proANP, NT-proBNP, proBNP1-108, and Tyr0-proBNP77-108. Fifteen peptides of 13-22 amino acids, spanning the sequences of NT-proANP and NT-proBNP, were prepared by solid-phase peptide synthesis. Two immunoassays for NT-proANP and four for NT-proBNP were set up, each with a different epitope specificity. The assays were applied for the measurement of NT-proANP and NT-proBNP in healthy individuals and in patients with acute myocardial infarction. The circulating molecular forms were analyzed by gel-filtration and reversed-phase HPLC. According to the HPLC analyses, circulating NT-proANP consists mainly of the full-length peptide, with some degradation at both ends. In contrast, circulating NT-proBNP is very heterogeneous. Most immunoreactive NT-proBNP is significantly smaller in size than NT-proBNP1-76, with truncation at both termini. The smallest fragments can be detected by assays directed at the central part of NT-proBNP only; assays directed at the ends gave 30-40% lower values. Despite the difference, the various assays correlated reasonably well with each other (r2 = 0.77-0.85). In patients with acute myocardial infarction, NT-proANP and NT-proBNP concentrations were 1.8-2.3 and 4.2-4.5 times higher than in healthy individuals. The development of heart failure further increased the concentrations. Molecular heterogeneity of the circulating forms causes a serious risk of preanalytical errors in assays for NT-proBNP and, to a lesser extent, NT-proANP. The development of a sandwich assay for NT-proBNP would be especially challenging. The most robust and reliable assays use antibodies directed at the central portions of NT-proANP or NT-proBNP.Keywords
This publication has 40 references indexed in Scilit:
- Cardiac Hormones as Diagnostic Tools in Heart FailureEndocrine Reviews, 2003
- N-Terminal Pro-B–Type Natriuretic Peptide and Long-Term Mortality in Acute Coronary SyndromesCirculation, 2002
- Natriuretic peptides in the diagnosis of heart disease—First amongst equals?International Journal of Cardiology, 2002
- The Prognostic Value of B-Type Natriuretic Peptide in Patients with Acute Coronary SyndromesNew England Journal of Medicine, 2001
- Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrationsThe Lancet, 2000
- Titration of vasodilator therapy in chronic heart failure according to plasma brain natriuretic peptide concentration: Randomized comparison of the hemodynamic and neuroendocrine effects of tailored versus empirical therapyAmerican Heart Journal, 1999
- Measurement and significance of circulating natriuretic peptides in cardiovascular diseaseClinical Science, 1998
- How Does Treatment Influence Endocrine Mechanisms in Acute Severe Heart Failure? Effects on Cardiac Natriuretic Peptides, the Renin System, Neuropeptide Y and CatecholaminesClinical Science, 1998
- Immunoradiometric assay for the N-terminal fragment of proatrial natriuretic peptidein human plasmaClinical Chemistry, 1998
- Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban populationThe Lancet, 1997